Symbols

OGN

Organon·NYSE

--(--)

OGN fundamentals

OGN Q4 2025 Earnings

Organon (OGN) released its earnings on Feb 12, 2026: revenue was 1.51B (YoY -5.34%), missed estimates; EPS was 0.63 (YoY -30.00%), missed estimates.

Revenue / YoY

1.51B

-5.34%

EPS / YoY

0.63

-30.00%

Report date

Feb 12, 2026

OGN Earnings Call Summary for Q4,2025

2025 Results: $6.2B revenue, $1.9B EBITDA, driven by biosimilar growth despite Nexplanon headwinds.
2026 Guidance: Flat revenue and EBITDA, with 75-100bps gross margin decline offset by OpEx savings.
Nexplanon Impact: 5-year label launch causes 13% volume dip in 2026, but ex-U.S. growth and REMS compliance mitigate risk.
Strategic Moves: Jada divestiture ($390M), $200M cost savings, and biosimilar expansion (denosumab launch).

Earnings

EPS

Revenue

Revenue & Expenses

OGN has released its 2025 Q4 earnings report, with revenue of 1.51B, reflecting a YoY change of -5.34%, and net profit of -205.00M, showing a YoY change of -288.07%. The Sankey diagram below clearly presents OGN's revenue sources and cost distribution.

Key Indicators

Organon (OGN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Organon (OGN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Organon (OGN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Organon (OGN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown